Journal of Cutaneous Medicine and Surgery

The Canadian Dermatology Association Announces 2023 Award Recipients

Retrieved on: 
Monday, June 19, 2023

OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is excited to announce this year’s recipients of its Member Awards and Public Education Awards.

Key Points: 
  • OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is excited to announce this year’s recipients of its Member Awards and Public Education Awards.
  • This award honours certified dermatologists who have made a lasting impact in dermatology through their professional accomplishments.
  • Dr. Peter Hull’s longstanding commitment to excellence in dermatology began in 1978 when he completed his dermatology training at the University of Pretoria.
  • The CDA Resident Writing Award recognizes dermatology residents who contribute and share their expertise and experiences within the dermatology community and have contributed significant knowledge in the dermatology field through publications.

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

Retrieved on: 
Wednesday, March 8, 2023

The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.

Key Points: 
  • The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.
  • Additionally, the consensus report endorses Castle’s DecisionDx®-Melanoma GEP risk stratification test as offering more utility than other existing CM GEP assays or nomograms, supported by extensive, evidence-driven data in current literature.
  • The panel reviewed 32 studies published between 2019 through 2022 assessing the use of GEP testing in CM prognosis.
  • Each of the recommendations was given a strength “A,” “B,” or “C” according to Strength of Recommendation Taxonomy (SORT) criteria.

DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook

Retrieved on: 
Tuesday, May 3, 2022

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2022 financial results and affirmed its full-year 2022 outlook.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2022 financial results and affirmed its full-year 2022 outlook.
  • We kicked off the year on a record pace for many of our key operating metrics and affirmed our full-year 2022 outlook, said John Dobak, M.D., CEO, DermTech.
  • The Company expanded its telehealth availability through DermTech Connect, which is now available in 44 states and represents 95% of the U.S. population.
  • The Company affirmed its full-year 2022 outlook for assay revenue between $22 million and $26 million.

DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma,” Published in SKIN: The Journal of Cutaneous Medicine

Retrieved on: 
Tuesday, March 8, 2022

It is used to identify high-risk lesions and help providers determine the next best treatment: either a biopsy and histopathologic evaluation or clinical surveillance of the lesion in question.

Key Points: 
  • It is used to identify high-risk lesions and help providers determine the next best treatment: either a biopsy and histopathologic evaluation or clinical surveillance of the lesion in question.
  • Comparatively, the traditional care pathway for evaluating suspicious moles is visual assessment, which is subjective, followed by a potentially avoidable surgical biopsy and histopathologic assessment.
  • This model predicted annual net savings of $0.54 PMPM for commercial health plans over a three-year period with incorporation of the PLA.
  • There is a clear need for objective, cost-effective technologies to help improve the assessment, classification and management of skin lesions and moles suspicious for melanoma, said Dr. Siegel.

Vial announces Dr. Mark Lebwohl to Scientific Advisory Board

Retrieved on: 
Tuesday, March 1, 2022

SAN FRANCISCO, March 1, 2022 /PRNewswire/ --The Vial Dermatology CRO announced the addition of Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board.

Key Points: 
  • SAN FRANCISCO, March 1, 2022 /PRNewswire/ --The Vial Dermatology CRO announced the addition of Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board.
  • Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.
  • The Vial Scientific Advisory Board's leading Dermatology KOLs will service sponsors in clinical strategy, regulatory strategy, trial design and indication selection.
  • Dr. Lebwohl stated: "The development of a technology-centric CRO that can drive much-needed progress in Dermatology research is exciting, and I'm delighted to join their Scientific Advisory Board."

DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine

Retrieved on: 
Tuesday, September 14, 2021

These results demonstrate that in this real-world intended use population, the PLA has an NPV of greater than 99%, confirming the high NPV established in previous clinical studies.

Key Points: 
  • These results demonstrate that in this real-world intended use population, the PLA has an NPV of greater than 99%, confirming the high NPV established in previous clinical studies.
  • Real-world PPV of 18.7% was determined by identifying melanoma diagnoses among PLA-positive lesions within a US-based registry of 3,418 PLA-tested cases.
  • The PLAs detection of genomic atypia enriched the pool of biopsied lesions nearly five-fold for those most likely to be diagnosed as high-risk or severely atypical and malignant.
  • The TRUST Study illustrates that the PLA can detect melanoma at the earliest stages when it is curable.